Login to Your Account

ImmuPharma, Cephalon Ink Potential $500M Lupuzor Deal

By Nuala Moran

Wednesday, November 26, 2008
LONDON - ImmuPharma plc took $15 million up front as the first payment in a potential $500 million deal, as it signed an agreement giving Cephalon Inc. the option on an exclusive, worldwide license to Lupuzor in the treatment of systemic lupus erythematosus. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription